Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1101/2020.06.18.20134353 http://scihub22266oqcxt.onion/10.1101/2020.06.18.20134353 33688686!7941663!33688686     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33688686.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       medRxiv 2021 ; ä (ä): ä Nephropedia Template TP {{tp|p=33688686|t=2021. IL-13 is a driver of COVID-19 severity |pdf=|usr=}}{{33688686}} gab.com Text IL-13 is a driver of COVID-19 severity JO: medRxiv http://www.kidney.de/pget.php?&tw=1&pmid=33688686 #FOAvip Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here we report that elevated interleukin-13 (IL-13) was associated with the need for mechanical ventilation in two independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab had less severe disease. In SARS-CoV-2 infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, in the lung, hyaluronan synthase 1 (Has1) was the most downregulated gene and hyaluronan accumulation was decreased. Blockade of the hyaluronan receptor, CD44, reduced mortality in infected mice, supporting the importance of hyaluronan as a pathogenic mediator, and indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and hyaluronan has important implications for therapy of COVID-19 and potentially other pulmonary diseases. Twit Text FOAVip IL-13 is a driver of COVID-19 severity ????medRxiv http://www.kidney.de/pget.php?&tw=1&pmid=33688686 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33688686 #FOAvip English Wikipedia <ref>{{Cite pmid|33688686}}</ref> IL-13 is a driver of COVID-19 severity #MMPMID33688686 Donlan AN; Sutherland TE; Marie C; Preissner S; Bradley BT; Carpenter RM; Sturek JM; Ma JZ; Moreau GB; Donowitz JR; Buck GA; Serrano MG; Burgess SL; Abhyankar MM; Mura C; Bourne PE; Preissner R; Young MK; Lyons GR; Loomba JJ; Ratcliffe SJ; Poulter MD; Mathers AJ; Day A; Mann BJ; Allen JE; Petri WA Jr medRxiv 2021[Mar]; ä (ä): ä PMID33688686show ga Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here we report that elevated interleukin-13 (IL-13) was associated with the need for mechanical ventilation in two independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab had less severe disease. In SARS-CoV-2 infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, in the lung, hyaluronan synthase 1 (Has1) was the most downregulated gene and hyaluronan accumulation was decreased. Blockade of the hyaluronan receptor, CD44, reduced mortality in infected mice, supporting the importance of hyaluronan as a pathogenic mediator, and indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and hyaluronan has important implications for therapy of COVID-19 and potentially other pulmonary diseases. äIL-13 is a driver of COVID-19 severity (epmc).pdf DeepDyve Pubget Overpricing